Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2007 2
2008 1
2009 2
2010 4
2011 6
2012 7
2013 8
2014 7
2015 7
2016 5
2017 6
2018 9
2019 5
2020 5
2021 13
2022 9
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Bakris GL, et al. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. JAMA. 2015. PMID: 26325557 Clinical Trial.
Coagulopathy in Acute Puumala Hantavirus Infection.
Koskela S, Mäkelä S, Strandin T, Vaheri A, Outinen T, Joutsi-Korhonen L, Pörsti I, Mustonen J, Laine O. Koskela S, et al. Among authors: makela s. Viruses. 2021 Aug 6;13(8):1553. doi: 10.3390/v13081553. Viruses. 2021. PMID: 34452419 Free PMC article. Review.
Severity Biomarkers in Puumala Hantavirus Infection.
Outinen TK, Mäkelä S, Pörsti I, Vaheri A, Mustonen J. Outinen TK, et al. Among authors: makela s. Viruses. 2021 Dec 28;14(1):45. doi: 10.3390/v14010045. Viruses. 2021. PMID: 35062248 Free PMC article. Review.
Kidney disease in Puumala hantavirus infection.
Mustonen J, Outinen T, Laine O, Pörsti I, Vaheri A, Mäkelä S. Mustonen J, et al. Among authors: makela s. Infect Dis (Lond). 2017 May;49(5):321-332. doi: 10.1080/23744235.2016.1274421. Epub 2017 Jan 3. Infect Dis (Lond). 2017. PMID: 28049381 Review.
Long-Term Consequences of Puumala Hantavirus Infection.
Mustonen J, Vaheri A, Pörsti I, Mäkelä S. Mustonen J, et al. Among authors: makela s. Viruses. 2022 Mar 14;14(3):598. doi: 10.3390/v14030598. Viruses. 2022. PMID: 35337005 Free PMC article.
Interleukin 34 in hantavirus infection.
Mustonen J, Mäkelä S. Mustonen J, et al. Among authors: makela s. Infect Dis (Lond). 2019 Nov-Dec;51(11-12):854-855. doi: 10.1080/23744235.2019.1672889. Epub 2019 Oct 3. Infect Dis (Lond). 2019. PMID: 31580193 No abstract available.
Uncovering the mysteries of hantavirus infections.
Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Mäkelä S, Mustonen J. Vaheri A, et al. Among authors: makela s. Nat Rev Microbiol. 2013 Aug;11(8):539-50. doi: 10.1038/nrmicro3066. Nat Rev Microbiol. 2013. PMID: 24020072 Review.
The evaluation of penicillin allergy in dialysis patients.
Sirkeoja S, Honkanen M, Huttunen R, Mäkelä S, Syrjänen J. Sirkeoja S, et al. Among authors: makela s. Nephrol Dial Transplant. 2023 Jul 31;38(8):1915-1917. doi: 10.1093/ndt/gfad072. Nephrol Dial Transplant. 2023. PMID: 37070969 No abstract available.
92 results